Drugs highlighted by Arthritis Care in its "Good News in Arthritis
campaign are to be investigated for possible side effects.
Arthritis treatments Celebrex and Vioxx - known as Cox-2 selective inhibitors - are to be the subject of a review by the European Medicines Evaluation Agency because of fears that they cause heart and stomach problems.
Cox-2s feature prominently in the Good News in Arthritis pack sent out on request as part of the campaign, which has been funded by manufacturers of Cox-2s, Pharmacia and Pfizer.
Neil Betteridge, head of public policy and campaigning at Arthritis Care, said that the charity had no plans to remove Cox-2 inhibitors from its literature. "An investigation is not a condemnation but safety is paramount. There seems to be a squabble between clinicians but anecdotally people tell us that Cox-2s have fewer side effects than older anti-inflammatory drugs."